Bruce E. Strober, MD, PhD, FAAD

Bruce E. Strober, MD, PhD, FAAD, is clinical professor of dermatology at Yale University School of Medicine in New Haven, CT, and the cofounder of Central Connecticut Dermatology in Cromwell, where he also practices. He is currently president of the International Psoriasis Council and scientific codirector of the CorEvitas Psoriasis Registry.

Dr Strober earned both his medical and his doctorate degrees from Columbia University College of Physicians and Surgeons and subsequently completed his residency in dermatology in the Department of Dermatology at New York University Grossman School of Medicine, both in New York, NY. Prior to cofounding Central Connecticut Dermatology, Dr Strober was a professor and chair, Department of Dermatology, University of Connecticut School of Medicine, in Farmington. He is board certified by the American Board of Dermatology and is a fellow in the American Academy of Dermatology.

His research interests include the study of therapeutics, both old and new, for inflammatory skin disease, specifically interventions that help patients with difficult-to-treat psoriasis, atopic dermatitis, and hidradenitis suppurativa. Additional research interests include elucidating novel features of inflammatory skin disease not previously uncovered and assisting in the clarification of the pathophysiology of inflammatory skin disease. He has served as principal investigator or subinvestigator for numerous multicenter clinical studies.

Dr Strober has served as editor in chief of the Journal of Psoriasis and Psoriatic Arthritis, a section editor for the British Journal of Dermatology, and an ad hoc reviewer for the Journal of the American Academy of Dermatology, JAMA Dermatology, the British Journal of Dermatology, and The New England Journal of Medicine. He has published book chapters and has coauthored more than 200 peer-reviewed manuscripts in journals such as JAMA Dermatology, The New England Journal of Medicine, the Journal of the American Academy of Dermatology, the Journal of Investigative Dermatology, and the Journal of the American Medical Association, among others.

Dr Strober has also frequently presented data to the US Food and Drug Administration, including to the Advisory Committee for secukinumab, a novel IL-17 inhibitor used for the treatment of psoriasis.